Early intervention to identify social needs means issues get caught sooner and patients can avoid or minimize financial toxicity, said Abra Kelson, MSW, LSWA-IC, medical social work supervisor, Northwest Medical Specialties.
Early intervention to identify social needs means issues get caught sooner and patients can avoid or minimize financial toxicity, said Abra Kelson, MSW, LSWA-IC, medical social work supervisor, Northwest Medical Specialties.
Transcript
What is the difference when there is early intervention for patients with social needs versus when issues get caught later?
Early intervention is so important when you talk about anything—financial, insurance. If someone is missed in that step, the doctor could have ordered treatment, scans, things like that, and they don’t have insurance or they’re not covered and now they have these bills for tens of thousands of dollars. That is going to lead to financial toxicity, to bankruptcy, possibly.
Being able to have someone in right away to say, "These are your benefits, these are where there might be gaps in your coverage or your cost of care might be high for you. Let’s get an assistance program in there right away." It goes the same for mental health, too. If someone is coming in with a new diagnosis, they also have untreated depression. That can also lead to poor outcomes, poor compliance with treatment. It’s really important that we are addressing the physical, the emotional, the spiritual. All of those aspects are equally important, in my eyes, to the cancer care experience.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More